Please login to the form below

Not currently logged in
Email:
Password:

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Immunogen has appointed Dr Charles Morris as the company's chief development officer.

Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech.

Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung cancer - IMGN853, in phase I for the treatment of ovarian, lung, and other cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.

ImmunoGen said it also expects to advance a fourth compound into clinic studies in 2013.

"Charlie has extensive experience leading the strategic development and registration of novel oncology compounds — expertise essential to ImmunoGen with our advancing and expanding product pipeline," said Daniel Junius, president and CEO of the company.

“We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company."

Dr Morris was previously executive VP and chief medical officer at Allos for two years, holding similar responsibilities as to his current role.

Prior to joining Allos, which was acquired in September by Spectrum Pharmaceuticals, he served as VPof  worldwide clinical research at US biopharma company Cephalon, where he helped with the development of oncology drug Treanda (bendamustine).

He has also spent time with AstraZeneca, where his roles included VP, clinical development projects in oncology.

27th November 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics